Hua Medicine
华领医药
Executive Summary
Hua Medicine is a Shanghai-based biotech focused on diabetes therapeutics, listed on HKEX (2552.HK) with clear BIOSECURE status. The company's flagship asset dorzagliatin represents a novel mechanism for diabetes treatment, positioning them as a potential licensing partner for US pharma seeking innovative metabolic disease assets. While geopolitically low-risk, limited public information on management team and corporate structure requires enhanced due diligence for any BD engagement.
Structure: As a Hong Kong-listed Chinese biotech, Hua Medicine likely operates through a VIE structure with offshore holding companies controlling mainland China operating entities. The lack of detailed subsidiary information suggests either a simplified structure or limited disclosure, requiring careful examination of corporate filings during due diligence to understand operational control and IP ownership structures.
BIOSECURE Risk
Company has clear BIOSECURE status with no BCC designation, indicating low regulatory risk for US partnerships
Key Exposures:
- •Potential future policy changes affecting Chinese biotechs
- •VIE structure complexities for IP transfers
Mitigation: Clear regulatory status provides good foundation, but specific BIOSECURE compliance measures unknown due to limited public information
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent deal activity data available, suggesting limited licensing track record
Approach: Approach with cautious interest given novel diabetes mechanism, but conduct thorough due diligence on management team, pipeline depth, and corporate structure before advancing discussions
Red Flags
- ⚠Limited public disclosure on key management team
- ⚠No visible recent corporate events or milestones
- ⚠Lack of subsidiary information raises corporate structure questions
- ⚠Unclear recent deal-making experience
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.